A forum for researchers, students and applicants in the field of cyclodextrin technology
Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator
The aim of this report is to review the literature and shed light on the uncertainties surrounding the use of
Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase
Remdesivir (GS-5734; Gilead Sciences Inc., US) is an investigational nucleoside analog that acts as a competitive inhibitor of viral RNAdependent
Pharmafile reports that Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections,
The systematic review published recently in Clinical Microbiology and Infection was based on 29 articles [1]. All studies except one
Advanced Science News published on the results of clinical trials of two vaccines against SARS-CoV-2. Three months ago, the University of
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Vaccines against COVID-19 will hopefully give broad parts of the human population a safe level of immunity and are considered
Amirian and Levy have recently collected the knowledge on remdesivir and its nucleoside analog [1]. This overview can be interesting
